Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU9D2F)

Drug Name
Gabexate Drug Info
Synonyms
gabexate; Gabexate [INN]; 39492-01-8; Gabexatum [INN-Latin]; Gabexato [INN-Spanish]; UNII-4V7M9137X9; CHEMBL87563; C16H23N3O4; Gabexate (INN); 4V7M9137X9; Ethyl p-hydroxybenzoate 6-guanidinohexanoate; ethyl 4-[6-(diaminomethylideneamino)hexanoyloxy]benzoate; Gabexatum; Gabexato; Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester; p-carbethoxyphenyl e-guanidinocaproate; AC1L1FYH; Prestwick3_001008; Prestwick2_001008; Prestwick0_001008; Prestwick1_001008; BSPBio_001135; SCHEMBL446024; SPBio_003016; GTPL7863
Indication
Disease Entry ICD 11 Status REF
Pancreatitis DC31-DC34 Approved [1]
Cross-matching ID
PubChem CID
3447
ChEBI ID
CHEBI:93036
CAS Number
CAS 39492-01-8
TTD Drug ID
DMU9D2F
VARIDT Drug ID
DR00837

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Serine protease unspecific (SP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nafamostat DMU1XOD Pancreatitis DC31-DC34 Approved [2]
Aprotinin DM0QD4W Bleeding disorder GA20-GA21 Approved [3]
Sivelestat sodium hydrate DMOSJD0 Acute lung injury NB32.3 Phase 4 [4]
Camostat DMQ7UL8 Cystic fibrosis CA25 Phase 2 [5]
VT-111a DMY9ZGN Acute coronary syndrome BA41 Phase 2 [6]
Sepimostat mesylate DMRBYH8 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 3 [7]
VT-111 DMOY15R Graft rejection in heart transplantation NE84 Preclinical [8]
NPI-1999 DMH1YL8 Thrombosis DB61-GB90 Terminated [9]
SDZ-MTH-958 DMKCXBJ Artery stenosis BD52 Terminated [10]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine protease unspecific (SP) TTEMV5X NOUNIPROTAC Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7863).
2 Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20.
3 Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding Clin Trials. 2005;2(3):218-29; discussion 229-32.
4 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
5 Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9.
6 Viral Serpin Therapeutics: From Concept to Clinic. Methods Enzymol. 2011; 499: 301-329.
7 Effect of FUT-187, oral serine protease inhibitor, on inflammation in the gastric remnant. Gan To Kagaku Ryoho. 1996 Dec;23(14):1971-9.
8 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
9 US patent application no. 2005,0096,323, Diketopiperazine derivatives to inhibit thrombin.
10 Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. Transplantation. 1996 Mar 27;61(6):862-8.